Pruritus News and Research

RSS
Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Data shows individualized regimens can help optimize prophylaxis treatment in hemophilia patients

Data shows individualized regimens can help optimize prophylaxis treatment in hemophilia patients

European Commission amends marketing authorisation for Celgene's REVLIMID

European Commission amends marketing authorisation for Celgene's REVLIMID

Headline results of Creabilis' CT327 Phase 2b trial in psoriasis patients announced

Headline results of Creabilis' CT327 Phase 2b trial in psoriasis patients announced

Maruishi gains exclusive rights to develop, commercialize Cara Therapeutics' CR845 in Japan

Maruishi gains exclusive rights to develop, commercialize Cara Therapeutics' CR845 in Japan

FDA grants Fast Track designation to Elorac's naloxone topical lotion

FDA grants Fast Track designation to Elorac's naloxone topical lotion

Halometasone and fusidic acid optimal for infected eczema

Halometasone and fusidic acid optimal for infected eczema

Laboratorios Grifols, Cadence announce new supply agreement for OFIRMEV

Laboratorios Grifols, Cadence announce new supply agreement for OFIRMEV

Regeneron, Sanofi announce pooled data from Phase 1b trials with dupilumab for atopic dermatitis

Regeneron, Sanofi announce pooled data from Phase 1b trials with dupilumab for atopic dermatitis

Otsuka receives FDA approval for ABILIFY MAINTENA to treat schizophrenia

Otsuka receives FDA approval for ABILIFY MAINTENA to treat schizophrenia

EMAS publishes clinical guide on lichen sclerosus in Maturitas journal

EMAS publishes clinical guide on lichen sclerosus in Maturitas journal

FDA approves Genzyme’s KYNAMRO to treat homozygous familial hypercholesterolemia

FDA approves Genzyme’s KYNAMRO to treat homozygous familial hypercholesterolemia

AMAG seeks FDA sNDA approval for Feraheme Injection

AMAG seeks FDA sNDA approval for Feraheme Injection

FDA approves GSK’s raxibacumab to treat inhalational anthrax

FDA approves GSK’s raxibacumab to treat inhalational anthrax

Top-line results from Durata Therapeutics’ dalbavancin Phase 3 study on ABSSSI

Top-line results from Durata Therapeutics’ dalbavancin Phase 3 study on ABSSSI

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

UCB to sponsor key sets of VIMPAT C-V data at 66th American Epilepsy Society annual meeting

UCB to sponsor key sets of VIMPAT C-V data at 66th American Epilepsy Society annual meeting

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma